Dr. Curt Bilby

Dr. Curt Bilby, the President and CEO of Terapio since 2007, has over twenty years of executive leadership experience in the biotechnology, healthcare and information technology sectors both domestically and in Europe. Previously, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation which developed a biosensor based on technology developed at the Naval Research Laboratory. Prior to that, he was the Chairman and CEO of Evacyte Corporation, a company developing laser-based cancer detection and cell diagnostics using technology developed at The University of Texas at Austin. Dr. Bilby also served as the Président-Directeur Général of the multi-national company Eurimed, S.A. headquartered in Paris, France. Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin. Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.

Broadcast 2189 (Special Edition)

Guest: Dr. Curt Bilby. Topics: Update on developing RLIP 76 as a radiation countermeasure drug as we as for possible use in space. Please direct all comments and questions regarding Space Show programs/guest(s) to the Space Show blog, http://thespaceshow.wordpress.com. Comments and questions should be relevant to the specific Space Show program. Written Transcripts of Space Show programs are a violation of our copyright and are not permitted without prior written consent, even if for your own use.


Subscribe to RSS - Dr. Curt Bilby